Strategy for cross-protection among Shigella flexneri serotypes
about
Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirusA multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiologyImmunology of Gut Mucosal VaccinesAttenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneri.Phenotypic and genotypic characterization of serologically atypical strains of Shigella flexneri type 4 isolated in Dhaka, Bangladesh.Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates.Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in miceShigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.Parameters underlying successful protection with live attenuated mutants in experimental shigellosisShigella isolates from the global enteric multicenter study inform vaccine development.Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Progress and pitfalls in Shigella vaccine research.Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.Shigella Vaccine Development: Finding the Path of Least Resistance.Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.An update on vaccines against Shigella.Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.Epidemiology and genetic characterization of Shigella flexneri strains isolated from three paediatric populations in Egypt (2000-2004).Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.Bacteriophages are the major drivers of Shigella flexneri serotype 1c genome plasticity: a complete genome analysis.Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex.Characterization of a serologically atypical Shigella flexneri Z isolated from diarrheal patients in Bangladesh and a proposed serological scheme for Shigella flexneriTwo novel mutations in among isolated from Jiangsu Province of China, 2016
P2860
Q26995690-B40BAAC5-D43D-464A-A501-C5563A9B5533Q28767862-082D135B-F81A-4527-9066-454B2A5782A6Q28972559-B332F945-AF07-40CB-910A-29F708F7D6ADQ33597022-DA9EB254-635F-40F8-B22A-26ABBB079B91Q33627338-327974F4-6722-40E8-9747-B8CD1D650922Q33962691-2880CA91-14A4-42F3-B87E-474E5EFF1BFFQ33987735-B6A8C1C2-172C-44EF-9DDC-72C1EEA04CA3Q34002272-CB136BCF-3B02-4441-8861-E67321111D29Q34003433-7AD00364-25F3-4593-A8C3-A3F5ED221889Q34006071-33FD8043-08F5-4FF7-9DFC-BBD592293811Q34202171-94E63B3F-EF93-4367-8870-6940EFBA499CQ34716080-A413972C-4D68-48A0-9A6A-C6B074446BDEQ36844719-EA12B718-9D53-4E72-ADC1-DDCD8A70DEF7Q37105553-35C096B1-EC15-4F4F-83FC-DDEE92109339Q37113756-D9240277-B5C2-4CF0-9028-D359BE874FABQ37163698-C846CD02-56E1-4CCD-B132-97AC239FF5D9Q37477191-1DFD2149-05EE-4AEA-9798-65A3018C1738Q37643320-ABCA9959-6C64-4A84-B6BF-E93B133D7BA8Q37668395-F121899A-B67B-4D48-A347-3AE02239A61DQ38776163-B74D3D91-5E97-4D92-AE0B-BD8E1AADDCE3Q38863954-2C79A1E2-5915-4382-A557-D515DA44130BQ39519924-EDC765E5-6F79-4BDA-9744-15EB4D5777E8Q40126474-2B3EAD1F-4C51-4926-B251-1E8B828AD59BQ41172706-A4224F67-AFF7-451B-A736-1F44AD1B10B6Q47093813-D25361CC-EA7D-4677-A448-912FC3755FC1Q52337397-899DE07E-FA94-4ADA-82F2-E5ADA88F4D7BQ57924523-F67D02C8-8353-4D57-A989-025067C31B8CQ57946228-44FA03C0-F559-4A14-A252-52451E205007
P2860
Strategy for cross-protection among Shigella flexneri serotypes
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Strategy for cross-protection among Shigella flexneri serotypes
@ast
Strategy for cross-protection among Shigella flexneri serotypes
@en
Strategy for cross-protection among Shigella flexneri serotypes
@nl
type
label
Strategy for cross-protection among Shigella flexneri serotypes
@ast
Strategy for cross-protection among Shigella flexneri serotypes
@en
Strategy for cross-protection among Shigella flexneri serotypes
@nl
prefLabel
Strategy for cross-protection among Shigella flexneri serotypes
@ast
Strategy for cross-protection among Shigella flexneri serotypes
@en
Strategy for cross-protection among Shigella flexneri serotypes
@nl
P2093
P2860
P1476
Strategy for cross-protection among Shigella flexneri serotypes
@en
P2093
P2860
P304
P407
P577
1999-02-01T00:00:00Z